MESOBLAST LTD
MESOMesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004.
Drugs in Pipeline
21
Phase 3 Programs
8
Upcoming Catalysts
2
Next Catalyst
Sep 4, 2026
18dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
Rexlemestrocel-L
Degenerative Disc Disease
adult human mesenchymal stem cells
Crohn's Disease
Prochymal®
Graft Versus Host Disease
remestemcel-L
Grade B aGVHD
PROCHYMAL adult human mesenchymal stem cells
Crohn's Disease
Infusion of one MPC expanded cord unit and one unexpanded cord unit
Acute Myelogenous Leukemia
Allogeneic Mesenchymal Precursor Cells (MPCs)
Chronic Heart Failure
Rexlemestrocel-L + HA mixture
Degenerative Disc Disease
Allogeneic Mesenchymal Precursor Cells
Rheumatoid Arthritis
Mesenchymal Precursor Cells (MPC) 12.5 M
Acute Myocardial Infarction
Prochymal™
Pulmonary Disease, Chronic Obstructive
Prochymal™ adult human mesenchymal stem cells
Crohn's Disease
Chondrogen
Recovery Following Partial Medial Meniscectomy
Prochymal® - 2 Million cells/kg
Graft Vs Host Disease
Single Dose MPCs Injection
Degenerative Disc Disease
Mesenchymal Stem Cells
Recovery Following Partial Medial Meniscectomy
Prochymal
Graft Versus Host Disease
MSB-CAR001 Combined With Hyaluronan
Anterior Cruciate Ligament Injury
Lumbar Interbody Fusion with Autograft
Degenerative Disc Disease
Mesenchymal Precursor Cells (MPCs)
Diabetic Nephropathy
NeoFuse
Cervical Degenerative Disc Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rexlemestrocel-L | Phase 3 | Degenerative Disc Disease | - | - |
adult human mesenchymal stem cells | Phase 3 | Crohn's Disease | - | - |
Prochymal® | Phase 3 | Graft Versus Host Disease | - | - |
remestemcel-L | Phase 3 | Grade B aGVHD | - | - |
PROCHYMAL adult human mesenchymal stem cells | Phase 3 | Crohn's Disease | - | - |
Infusion of one MPC expanded cord unit and one unexpanded cord unit | Phase 3 | Acute Myelogenous Leukemia | - | - |
Allogeneic Mesenchymal Precursor Cells (MPCs) | Phase 3 | Chronic Heart Failure | - | - |
Rexlemestrocel-L + HA mixture | Phase 3 | Degenerative Disc Disease | - | - |
Allogeneic Mesenchymal Precursor Cells | Phase 2 | Rheumatoid Arthritis | - | - |
Mesenchymal Precursor Cells (MPC) 12.5 M | Phase 2 | Acute Myocardial Infarction | - | - |
Prochymal™ | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
Prochymal™ adult human mesenchymal stem cells | Phase 2 | Crohn's Disease | - | - |
Chondrogen | Phase 2 | Recovery Following Partial Medial Meniscectomy | - | - |
Prochymal® - 2 Million cells/kg | Phase 2 | Graft Vs Host Disease | - | - |
Single Dose MPCs Injection | Phase 2 | Degenerative Disc Disease | - | - |
Mesenchymal Stem Cells | Phase 2 | Recovery Following Partial Medial Meniscectomy | - | - |
Prochymal | Phase 2 | Graft Versus Host Disease | - | - |
MSB-CAR001 Combined With Hyaluronan | Phase 2 | Anterior Cruciate Ligament Injury | - | - |
Lumbar Interbody Fusion with Autograft | Phase 2 | Degenerative Disc Disease | - | - |
Mesenchymal Precursor Cells (MPCs) | Phase 2 | Diabetic Nephropathy | - | - |
NeoFuse | Phase 2 | Cervical Degenerative Disc Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in MESOBLAST LTD's drug pipeline?→
CatalystAlert tracks 21 drug candidates in MESOBLAST LTD's (MESO) pipeline across Phase 3, Phase 2. Its lead program is Rexlemestrocel-L (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MESOBLAST LTD's next FDA catalyst?→
MESOBLAST LTD's (MESO) next tracked catalyst is a Earnings expected September 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MESO biotech catalysts?→
Add MESO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MESOBLAST LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.